Loading clinical trials...
Loading clinical trials...
Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study
Conditions
Interventions
Alemtuzumab i.v.
Alemtuzumab s.c.
Locations
6
Germany
Medizinische Universitaetsklinik I at the University of Cologne
Cologne, Germany
Klinikum Barnim GmbH, Werner Forssmann Krankenhaus
Eberswalde, Germany
Universitatsklinikum Heidelberg
Heidelberg, Germany
Klinikum Lippe - Lemgo
Lemgo, Germany
III Medizinische Klinik Mannheim
Mannheim, Germany
Krankenhaus Barmherzige Brueder Regensburg
Regensburg, Germany
Start Date
November 1, 2003
Primary Completion Date
January 1, 2010
Completion Date
February 17, 2012
Last Updated
June 13, 2019
NCT05006716
NCT07277231
NCT06859424
NCT01804686
NCT05254743
NCT05371808
Lead Sponsor
German CLL Study Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions